Elsevier launches new PharmaPendium, empowering pharma companies to bring novel drugs to market faster and increase success of regulatory submissions

Elsevier, a global leader in information and data analytics, has launched the new PharmaPendium, sharpening the translational view of a platform that combines extensive preclinical and clinical data, including complete Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval packages, with predictive tools to accelerate drug development. PharmaPendium enables companies to make faster, more informed decisions about what drug candidates to advance. Pharma professionals and researchers can use the tool to benchmark against competitors, prioritize safety and efficacy, and develop effective strategies for regulatory submissions. The depth and reliability of the platform’s data means PharmaPendium is already trusted by the FDA, Pharmaceuticals and Medical Devices Agency (PMDA) and the top 20 global pharma companies.

“Translation of preclinical research findings to humans in an efficient but safe way is one of the greatest challenges facing drug developers. We designed the new PharmaPendium to solve this. The platform leverages Elsevier’s expertise in curating scientific data and presents it in an intuitive and meaningful way for pharma professionals,” adds Olivier Barberan, Director of Translational Medicine Solutions at Elsevier. “This improved access to highly relevant data plus predictive tools enhances regulatory success, safeguarding the massive investments of pharma companies.”

PharmaPendium’s advanced predictive tools include the Drug-Drug Interaction Risk Calculator (DDIRC) and Safety Margin Tool. These solutions empower researchers to accurately predict harmful drug-drug interactions and off-target related clinical adverse events, and to optimize nonclinical studies and reduce animal testing. They were co-designed to meet industry needs and align with regulatory guidance. Elsevier collaborated with Novartis on the Safety Margin Tool, and with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others on the DDIRC.

Today, 93% of drugs entering clinical trials fail to secure regulatory approval. Better understanding of first-in-human dose selection, optimal study endpoints and mitigating adverse events improves regulatory success. Yet translation from preclinical studies to post-market data analysis is time-consuming and expensive. The new PharmaPendium helps overcome these challenges with:

• Enhanced visualization tools to more easily gain insights from vast quantities of data

• Intelligent autocomplete to increase discoverability and identify important concepts

• Improved search results interface to quickly access key data, such as drug metabolism and pharmacokinetics (DMPK), efficacy and chemistry, extracted from leading data sources, including:

  • Complete FDA and EMA approval packages and FDA advisory committee documents

  • 19 million reports from the FDA Adverse Event Reporting System (FAERS)

  • DESI (Drug Efficacy Study Implementation) documents, Meyler's 16th Edition, Mosby's Drug Consult™️ and scientific articles

PharmaPendium’s high-quality datasets are machine readable and available for off-platform use, allowing companies to embed data into their workflows and employ predictive and scenario modelling. Customers can also access support from Elsevier’s team of domain and data science experts for their data projects.

Learn more about PharmaPendium

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야를 선도하는 글로벌 기업입니다. 100년 넘게 과학과 의료의 발전을 뒷받침하며 인류의 더 나은 미래를 위해 노력해왔습니다. 우리는 전 세계 170개국의 대학 및 기업 연구자, 의사, 간호사, 차세대 보건의료 인력과 교육자들이 중요한 업무를 수행할 수 있도록 지원하고 있습니다. 우리는 신뢰할 수 있는 근거 기반의 과학과 의학 콘텐츠에 첨단 인공지능(AI) 기술을 접목한 핵심 인사이트와 혁신적인 솔루션을 제공함으로써, 이들의 더 나은 성과 달성을 돕고자 합니다. 우리는 제품과 조직 문화 전반에 포용성과 지속 가능성의 가치를 반영하고, 함께하는 커뮤니티와의 협력을 통해 이를 실천해 나가고 있습니다. 엘스비어 재단(Elsevier Foundation)은 세계 곳곳에서 연구 및 보건 분야의 협력 사업을 후원하고 있습니다.

엘스비어는 전문가 및 비즈니스 고객을 위한 정보 기반 분석 및 의사결정 도구를 제공하는 글로벌 기업 RELX의 계열사입니다. 자세한 내용은 www.elsevier.com에서 확인하실 수 있으며, SNS @ElsevierConnect를 통해 최신 소식도 실시간으로 받아보실 수 있습니다.